Discounted Cash Flow

Teva Pharmaceutical Industries Ltd. ADR

TEVA · Based on 10 years of SEC filings

DCF estimate unavailable — only_3_profitable_out_of_10

Average annual growth rates

Metric 10-Year 5-Year 3-Year
Sales
Free Cash Flow
Average (FCF & NI)
Net Income

Average annual growth is the mean year-over-year change across each period.

Endpoint CAGR (better for long term trend)

Metric 10-Year 5-Year 3-Year
Sales
Free Cash Flow
Average (FCF & NI)
Net Income

Endpoint CAGR is the compound annual rate from the first to last year in each period.

Projections use average year-over-year growth. Change this in Settings.

Projected growth rate

Free cash flow growth
10-year: — 5-year: — 3-year: —
Averaged growth (FCF & NI)
10-year: — 5-year: — 3-year: —
Net income growth
10-year: — 5-year: — 3-year: —
Sales growth (not added to calculations)
10-year: — 5-year: — 3-year: —

Click a greyed-out slider to switch metrics. Slide between the 10-year, 5-year, and 3-year historic growth rates for FCF, net income, or their average.

%
%

Historical inputs (10 fiscal years)

YEAR Sales Net Income Free Cash Flow Net Margin EPS (diluted)
2016 $21.9b $68.0m $4.3b 0.3% $0.07
2017 $22.4b (2.2%) $-16.3b (-24019.1%) $1.4b (-68.8%) -72.7% (-23504.1%) $-16.26 (-23328.6%)
2018 $18.9b (-15.8%) $-2.1b (86.8%) $1.8b (32.9%) -11.4% (84.3%) $-2.35 (85.5%)
2019 $16.9b (-10.4%) $-999.0m (53.5%) $223.0m (-87.6%) -5.9% (48.1%) $-0.91 (61.3%)
2020 $16.7b (-1.4%) $-4.0b (-299.4%) $638.0m (186.1%) -24.0% (-304.9%) $-3.64 (-300.0%)
2021 $15.9b (-4.7%) $417.0m (110.5%) $236.0m (-63.0%) 2.6% (111.0%) $0.38 (110.4%)
2022 $14.9b (-6.0%) $-2.4b (-664.3%) $1.0b (341.5%) -15.8% (-700.3%) $-2.12 (-657.9%)
2023 $15.8b (6.2%) $-559.0m (76.2%) $842.0m (-19.2%) -3.5% (77.6%) $-0.50 (76.4%)
2024 $16.5b (4.4%) $-1.6b (-193.2%) $749.0m (-11.0%) -9.9% (-180.8%) $-1.45 (-190.0%)
2025 $17.3b (4.3%) $1.4b (186.0%) $1.1b (53.3%) 8.2% (182.5%) $1.23 (184.8%)

Base FCF: (latest fiscal year)

Discount rate: %

Terminal growth:

Projection period: years

Alt A decline yrs:

Alt B total yrs:

Values abbreviated: b = billions, m = millions, k = thousands.

Projected cash flows

Year Projected cash flow Discount Factor Present Value

PV of projected FCF:

Terminal FCF:

Terminal value:

PV of terminal value:

Enterprise value (DCF):

DCF price per share:

Current price:

Alternative DCF Models

Model Fair Value Upside PV(FCFs) PV(Terminal) Total Years
Standard (10yr→TV) 10 + TV
Alt A (Gradual Decline)
Alt B (30yr Hard Stop) N/A

This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.

+ 10YR Financials Balance Sheet (10YR) Cash Flow (10YR) DCF Model

only_3_profitable_out_of_10

Once the company meets all DCF eligibility criteria (sufficient history, profitability, growth trends), an estimate will become available automatically. No action is needed.